Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights

SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and MannKind Corporation from 2014 to 2023. Over this period, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by over 17,000% from 2014 to 2023. In contrast, MannKind Corporation's expenses have remained relatively stable, with a modest increase of about 19% over the same period.

Key Insights

• Apellis Pharmaceuticals: The company's SG&A expenses surged, particularly from 2020 onwards, reflecting its aggressive expansion and marketing strategies.
• MannKind Corporation: Despite fluctuations, MannKind maintained a more consistent spending pattern, indicating a steady operational approach.

This financial journey highlights the contrasting strategies of these two biotech firms, offering valuable insights for investors and industry analysts alike.